Cardiac valve replacement with glutaraldehyde preserved aortic allografts

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Pediatric Cardiology

Background:

• Cardiac valve replacement is crucial for patients with severe valve disease.
• Allografts offer a biological alternative for valve repair or replacement.
• Pediatric patients present unique challenges for prosthetic valve durability.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of glutaraldehyde preserved stent mounted aortic allografts in pediatric cardiac valve replacement.
• To assess survival rates, valve-related complications, and reoperation incidence.
• To compare outcomes with existing pediatric valve prostheses.

Main Methods:

• A retrospective analysis of 144 patients undergoing cardiac valve replacement between 1984 and 1988.
• Use of glutaraldehyde preserved stent mounted aortic allografts for various valve positions.
• Long-term follow-up to assess survival, complications (calcification), and reoperations.

Main Results:

• Hospital mortality was 2.8%.
• Five-year actuarial survival was 73.8%, with 81.4% for patients 15 years or younger.
• Calcification was the primary complication (3.0%/patient-year), especially in younger patients, leading to valve dysfunction in 17.4% at 5 years.
• Five-year freedom from calcification-related valve dysfunction was 82.6% overall and 69.9% in those 15 or younger.
• Reoperation incidence was 3.3%/patient-year.

Conclusions:

• Glutaraldehyde preserved stent mounted aortic allografts demonstrate acceptable short-to-mid-term outcomes in pediatric cardiac valve replacement.
• Fibrocalcification is a significant concern, particularly in younger pediatric patients, impacting long-term valve durability.
• These allografts show superior freedom from primary valve failure due to calcification compared to xenobioprostheses in the pediatric age group.